Sommaire

• • ·Table of Contents

    Page :i

    
• • ·Editorial Board

    Page :iii

    
• • ·Information for Readers

    Page :iv

    

• Editorials

  • ·Frailty and multi-morbidities should not govern oral anticoagulation therapy prescribing for patients with atrial fibrillation

    Page :120-122

    Ameenathul M Fawzy, Brian Olshansky, Gregory Y H Lip

    

• Trial Designs

  • ·The appropriateness of coronary investigation in myocardial injury and type 2 myocardial infarction (ACT-2): A randomized trial design

    Page :11-20

    Kristina Lambrakis, John K. French, Ian A. Scott, Tom Briffa, David Brieger, Michael E. Farkouh, Harvey White, Anthony (Ming-Yu) Chuang, Kathryn Tiver, Stephen Quinn, Billingsley Kaambwa, Matthew Horsfall, Erin Morton, Derek P Chew

    Résumé Résumé Plan Plan  
  • ·BEtablocker Treatment After acute Myocardial Infarction in revascularized patients without reduced left ventricular ejection fraction (BETAMI): Rationale and design of a prospective, randomized, open, blinded end point study

    Page :37-46

    John Munkhaugen, Vidar Ruddox, Sigrun Halvorsen, Toril Dammen, Morten W Fagerland, Kjersti H Hernæs, Nils Tore Vethe, Eva Prescott, Svend Eggert Jensen, Olaf Rødevand, Jarle Jortveit, Bjørn Bendz, Henrik Schirmer, Lars Køber, Hans Erik Bøtker, Alf Inge Larsen, Kjell Vikenes, Terje Steigen, Rune Wiseth, Terje Pedersen, Thor Edvardsen, Jan Erik Otterstad, Dan Atar

    Résumé Résumé Plan Plan  
  • ·Home monitoring with IT-supported specialist management versus home monitoring alone in patients with heart failure: Design and baseline results of the SUPPORT-HF 2 randomized trial

    Page :55-64

    SUPPORT-HF 2 Investigators and Committees 1 kazem.rahimi@georgeinstitute.ox.ac.uk

    Résumé Résumé Plan Plan   

• Clinical Investigations

  • ·Twenty-five year trends (1986-2011) in hospital incidence and case-fatality rates of ventricular tachycardia and ventricular fibrillation complicating acute myocardial infarction

    Page :1-10

    Hoang V. Tran, Arlene S. Ash, Joel M. Gore, Chad E. Darling, Catarina I. Kiefe, Robert J. Goldberg

    Résumé Résumé Plan Plan  
  • ·Attitudes and considerations of patients with ST-elevation myocardial infarction toward participation in randomized clinical trials

    Page :21-27

    Christoffer Polcwiartek, Pia Behrndtz, Ann Hass Andersen, Marianne Bregendahl, Helle Pedersen Hald, Svend Eggert Jensen

    Résumé Résumé Plan Plan  
  • ·Sex differences in management and outcomes of patients with stable symptoms suggestive of coronary artery disease: Insights from the PROMISE trial

    Page :28-36

    Neha J. Pagidipati, Adrian Coles, Kshipra Hemal, Kerry L. Lee, Rowena J. Dolor, Patricia A. Pellikka, Daniel B. Mark, Manesh R. Patel, Sheldon E. Litwin, Melissa A. Daubert, Svati H. Shah, Udo Hoffmann, Pamela S. Douglas, PROMISE Investigators

    Résumé Résumé Plan Plan   
  • ·Accelerated coronary atherosclerosis not explained by traditional risk factors in 13% of young individuals

    Page :47-54

    Trajen Head, Lisa Henn, Victor P. Andreev, Edward E. Herderick, Sapna K. Deo, Sylvia Daunert, Pascal J. Goldschmidt-Clermont

    Résumé Résumé Plan Plan   
  • ·Characterization of cardiovascular clinical events and impact of event adjudication on the treatment effect of darapladib versus placebo in patients with stable coronary heart disease: Insights from the STABILITY trial

    Page :65-73

    Claes Held, Harvey D. White, Ralph A.H. Stewart, Richard Davies, Shani Sampson, Karen Chiswell, Adam Silverstein, Renato D. Lopes, Ulrika Heldestad, Andrzej Budaj, Kenneth W Mahaffey, Lars Wallentin, on behalf of the STABILITY Investigators

    Résumé Résumé Plan Plan  
  • ·The association of pre- and posthospital medication adherence in myocardial infarction patients

    Page :74-80

    Jacob A. Doll, Anne S. Hellkamp, Laine Thomas, Gregg C. Fonarow, Eric Peterson, Tracy Y Wang

    Résumé Résumé Plan Plan   
  • ·The CSL112-2001 trial: Safety and tolerability of multiple doses of CSL112 (apolipoprotein A-I [human]), an intravenous formulation of plasma-derived apolipoprotein A-I, among subjects with moderate renal impairment after acute myocardial infarction

    Page :81-90

    C. Michael Gibson, Mathieu Kerneis, Megan K. Yee, Yazan Daaboul, Serge Korjian, Ali Poyan Mehr, Pierluigi Tricoci, John H. Alexander, John J.P. Kastelein, Roxana Mehran, Christoph Bode, Basil S. Lewis, Ravindra Mehta, Danielle Duffy, John Feaster, Majdi Halabi, Dominick J. Angiolillo, Daniel Duerschmied, Ton Oude Ophuis, Bela Merkely

    Résumé Résumé Plan Plan   
  • ·The prognostic value of various biomarkers in adults with pulmonary hypertension; a multi-biomarker approach

    Page :91-99

    Laurie W. Geenen, Vivan J.M. Baggen, Thomas Koudstaal, Karin A. Boomars, Jannet A. Eindhoven, Eric Boersma, Jolien W. Roos-Hesselink, Annemien E. van den Bosch

    Résumé Résumé Plan Plan   
  • ·Modes of death and prognostic outliers in chronic heart failure

    Page :100-109

    Marco Canepa, Pietro Ameri, Donata Lucci, Gian Luigi Nicolosi, Roberto Marchioli, Maurizio Porcu, Gianni Tognoni, Maria Grazia Franzosi, Roberto Latini, Attilio Maseri, Luigi Tavazzi, Aldo Pietro Maggioni, GISSI-HF Investigators 1

    Résumé Résumé Plan Plan   
  • ·Secular trends in success rate of catheter ablation for atrial fibrillation: The SMASH-AF cohort

    Page :110-119

    Alexander C. Perino, George C. Leef, Andrew Cluckey, Fahd N. Yunus, Mariam Askari, Paul A. Heidenreich, Sanjiv M. Narayan, Paul J. Wang, Mintu P. Turakhia

    Résumé Résumé Plan Plan   
  • ·Outcomes of apixaban versus warfarin in patients with atrial fibrillation and multi-morbidity: Insights from the ARISTOTLE trial

    Page :123-131

    Karen P. Alexander, Marc A. Brouwer, Hillary Mulder, Dragos Vinereanu, Renato D. Lopes, Marco Proietti, Sana M. Al-Khatib, Ziad Hijazi, Sigrun Halvorsen, Elaine M. Hylek, Freek W.A. Verheugt, John H. Alexander, Lars Wallentin, Christopher B. Granger, ARISTOTLE Investigators

    Résumé Résumé Plan Plan